

FINASTERIDE 5MG  
**FINASTEKERN**  
KERNPHARMA

MADE IN SPAIN

MARKETING TEAM

## BENIGN PROSTATIC HYPERPLASIA

BPH

- Age-related disease;
- Non cancerous increase in size of the prostate;

3 /  
1000

CASES  
MEN 45 - 49  
YEARS OLD

BPH was one of the ten most common and costly diseases in men older than 50 years of age in a study conducted in the USA in 2014.

Incidence rates increase from 3 cases per 1000 man/year at age 45-49 years, to 38 cases per 1000 man/year by the age of 75-79 years.

38 /  
1000

CASES  
MEN 75 - 79  
YEARS OLD

## SIGNS & SYMPTOMS



INVOLUNTARY  
URINATION AT NIGHT



BLADDER PAIN  
OR PAIN WHILE URINATING



URGE TO URINATE  
FREQUENTLY



INVOLUNTARY  
INTERRUPTION

# FINASTERIDE 5MG FINASTEKERN KERNPHARMA



## A TREATMENT FOR BPH

### MODE OF ACTION

FINASTEKERN is a type II & III 5 $\alpha$ -reductase inhibitor.

5- $\alpha$  reductase is the enzyme that metabolizes Testosterone into Dihydrotestosterone (DHT), that is a critical mediator of prostate growth.

DHT is ten times more potent than testosterone, as it dissociates from the androgen receptor more slowly.

DHT can act in an autocrine fashion or in a paracrine fashion by binding to nuclear androgen receptors and signaling the transcription of growth factors.

Therapy with a 5 $\alpha$ -reductase inhibitor markedly reduces the DHT content of the prostate and, in turn, reduces prostatic volume and BPH symptoms.

### CLINICAL USE

- BPH
- Lower urinary tract symptoms
- Androgenic alopecia
- Prostate cancer
- Hirsutism in women

### LIFESTYLE CHANGES

- Physical activity
- Moderate caffeine & alcohol intake
- Avoid anticholinergic medications
- Urinate in sitting positions

### SURGERY

Surgery is possible in severe cases. The surgical approach - the prostatectomy - consists of the partial or complete removal of the prostate.

FINASTERIDE 5MG  
FINASTEKERN  
5 $\alpha$ -reductase inhibitor